This Study Include Asthma Chronic Obstructive Pulmonary Disease (COPD) Overlap Patients.Patients Were Vitamin D Deficient.Age Range 40-70 Years, Smokers.Patients Were Advised to Take Either Placebo or Vitamin D3.Lung Functions and Exercise Tolerance Were Assessed at Baseline and at 26th Weeks.

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (143 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-02-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: dlserumpatientstatuscardiac
  Phrases that lowered it: asthmamalediseasesbmimellitus
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Minimum age: 40 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 7.3% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Primary purpose: supportive care (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 65.0% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: none (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Maximum age: 70 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Vitamin D3 on Lung Function and Exercise Tolerance in COPD Patients NCT03781895 · started 2017 · scored riskier than 10% of active trials completed
• Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma NCT01248065 · started 2011 · scored riskier than 17% of active trials completed
• Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations. NCT01395589 · started 2011 · scored riskier than 7% of active trials completed
• Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma) NCT02687815 · started 2016 · scored riskier than 16% of active trials terminated
• Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency NCT01131858 · started 2010 · scored riskier than 10% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.